Don't Infuse in Patients
ROCKVILLE, MD- The Food and Drug Administration (FDA) has issued a warning that triCitrasol may cause death when infused into patients. TriCitrasol is a 46.7% concentration of sodium citrate anticoagulant used to keep bloodlines open. A case has been discovered in which a patient died of cardiac arrest after triCitrasol was injected full strength into a hemodialysis permanent blood access catheter that had just been implanted. Rapid or excessive infusion of citrate solutions can cause fatal heart rhythm disruption, seizures, or bleeding due to loss of blood calcium.
TriCitrasol is manufactured by Cytosol Laboratories and is distributed by Medcomp. Both companies voluntarily recalled the product for use with blood access catheters. TriCitrasol is also used to prepare white cells for transfusion and is still available for that purpose.
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.